GlassScriptPhysician profile
Adam R Shapira
NPI 1942472386
$8,968.89
in general payments reported to CMS, 2019-2025
34 companies · $1,018 in 2025
The $1,018 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,750 · 2020: $498 · 2021: $365 · 2022: $1,664 · 2023: $1,962 · 2024: $712 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,268 · Travel and Lodging: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.00 |
| Travel and Lodging | $423.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,995.39 | 2019-2025 | Ensite, Aveir, Tacticath Ablation Catheter, Sensor Enabled |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,634.38 | 2019 | |
| Medtronic, INC. | $643.59 | 2023 | Arctic Front Advance, Na |
| Cardiva Medical, INC. | $329.43 | 2021-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Atricure, INC. | $321.15 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Philips North America LLC | $313.10 | 2020-2025 | (Ck7) Extended Holter, Extended Holter, Ecc Solutions |
| Boston Scientific Corporation | $232.41 | 2023-2025 | Apollo Esg System, Watchman Access System |
| Biosense Webster, INC. | $205.52 | 2023 | Carto 3 |
| Aop Health US, LLC | $185.59 | 2025 | Rapiblyk |
| Lundbeck LLC | $152.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $131.76 | 2019-2023 | |
| Altathera Pharmaceuticals LLC | $130.66 | 2022-2025 | Sotalol Hydrochloride |
| Janssen Pharmaceuticals, INC | $124.78 | 2019-2020 | |
| Cordis US Corp. | $55.35 | 2024-2025 | Mynx Control Venous, Mynx Control |
| Amgen INC. | $50.33 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $50.12 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Davol INC. | $48.16 | 2022 | |
| Edwards Lifesciences Corporation | $42.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.99 | 2022-2024 | Eliquis |
| Impulse Dynamics (USA) INC. | $33.41 | 2023 | Optimizer |
| Medicomp INC | $30.38 | 2025 | Telepatch Cardiac Monitor |
| Kestra Medical Technology Services, INC. | $27.11 | 2025 | Assure Wcd |
| Bardy Diagnostics, INC. | $24.61 | 2019 | |
| Recor Medical INC | $24.35 | 2025 | Paradise Ultrasound Renal Denervation System |
| Pfizer INC. | $23.27 | 2025 | |
| Angiodynamics, INC. | $23.09 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.27 | 2021 | |
| Stryker Corporation | $16.38 | 2021 | |
| Elutia, INC. | $14.96 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.77 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.63 | 2021 | |
| Amarin Pharma, INC. | $13.64 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$126,689.87 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Shapira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.